Maze Therapeutics今日股价盘中大涨6.25%,引发市场广泛关注。
消息显示,Maze Therapeutics在今日的IPO中定价为每股16美元,中值于此前公布的定价区间。公司将发行875万股股票,计划募资1.4亿美元。
Maze Therapeutics专注于开发治疗肾脏、心脏和代谢疾病的药物,拥有1.496亿美元的现金储备。该公司的最大股东是Third Rock Ventures的子公司,其他投资者包括ARCH Venture Partners的子公司等知名投资机构。成功IPO将为其持续的药物研发提供资金支持,这可能是促使其股价上涨的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.